Manufacturers Life Insurance Company acquired 21,597 shares of GRAIL, Inc. during the second quarter. The new stake is valued at approximately $1.474 million according to a recent SEC filing. This move follows several other institutional investors who recently modified their holdings in the healthcare firm.
GRAIL is currently seeking FDA approval for its Galleri multi-cancer early detection test. A key advisory committee meeting is scheduled for September 23, 2026. The company anticipates receiving formal approval in early 2027.
Regulatory clearance is a critical milestone for securing broader insurance coverage. This approval is expected to drive widespread commercial adoption of the detection technology.